Alzheimer's Disease: AAIC Review from "Fierce Biotech"

Alzheimer's roundup: Investigators carve out small gains against a brutal diseaseFierce BiotechBy John CarrollJuly 18, 2013 Read the article
Source: BrainBlog - Category: Neurologists Source Type: blogs

Related Links:

CONCLUSIONS: Brain 18F-FDG PET had an elevated performance in the early diagnosis of PPA variants and in the advanced PPA AD/FTD classification. QL clarified the development of AD or FTD in advanced PPA cases and supported the differential diagnosis of a PPA variant in a few early cases. QN 18F-FDG PET evaluation better contributed to the early diagnosis of an unclear metabolic pattern. To correctly identify all cases, patients with diffuse cortical hypometabolism were also included. Larger series are necessary to confirm these data. PMID: 32062656 [PubMed - as supplied by publisher]
Source: Dementia and Geriatric Cognitive Disorders - Category: Psychiatry Tags: Dement Geriatr Cogn Disord Source Type: research
Authors: Xiong C, Luo J, Coble D, Agboola F, Kukull W, Morris JC Abstract INTRODUCTION: We aim to determine racial disparities and their modifying factors in risk for Alzheimer's disease (AD) dementia among cognitively normal individuals 65 years or older. METHODS: Longitudinal data from the National Alzheimer's Coordinating Center Uniform Data Set on 1229 African Americans (AAs) and 6679 whites were analyzed for the risk of AD using competing risk models with death as a competing event. RESULTS: Major AD risk factors modified racial differences which, when statistically significant, occurred only with olde...
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
Abstract Mitochondrial dysfunction is an early event of Alzheimer's disease (AD), contributes the onset and progression of AD, and may represent an effective therapeutic target for AD intervention. Since mitochondria in central neurons are more susceptible to oxidative damage than non-neuronal cells, the specific delivery of the antioxidants to the mitochondria of impaired central neurons is crucial for achieving the therapeutic effect on AD. Here, we prepare the neuronal mitochondria-targeted micelles (CT-NM) through co-decoration with neural cell adhesion molecule (NCAM) mimetic peptide C3 for brain neuron speci...
Source: Biomaterials - Category: Materials Science Authors: Tags: Biomaterials Source Type: research
ConclusionsBased on these results, we suggest that DSS play a positive effective role in increasing DHA content by up-regulating iPLA2 and 15-LOX, resulting in ameliorating oxidative stress and inflammation and finally ameliorating cognition deficits in APP/PS1 mice.Graphical abstract
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
CONCLUSIONS The results indicate that, although persons with disabilities can exhibit a wide functional range, they remain at risk of PUs and should be evaluated for proper preventive measures, including support surfaces and wheelchair cushions.
Source: Advances in Skin and Wound Care - Category: Dermatology Tags: ORIGINAL INVESTIGATION Source Type: research
Conditions:   Alzheimer Disease;   Healthy Volunteer Intervention:   Drug: [11C]PBR28 and[18F]NOS Sponsor:   University of Pennsylvania Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Publication date: 1 April 2020Source: Journal of Molecular Liquids, Volume 303Author(s): Faisal Ameen, Sharmin Siddiqui, Ishrat Jahan, Shahid M. Nayeem, Sayeed ur Rehman, Mohammad TabishAbstractMemantine is an NMDA receptor antagonist used to treat Alzheimer's disease. Detailed insight about the interaction between memantine and bovine serum albumin (BSA) was obtained through multi spectroscopic techniques and in silico analysis. UV–visible, steady-state fluorescence spectra, and resonance light scattering (RLS) studies showed the complex formation between memantine and BSA. The binding constant for the BSA-memantine...
Source: Journal of Molecular Liquids - Category: Molecular Biology Source Type: research
Researchers here provide evidence for significant levels of cell death to occur in the brain earlier than expected in the development of Alzheimer's disease, during the stage of mild cognitive impairment thought to be driven by the aggregation of amyloid-β. The researchers identify some portions of a mechanism by which amyloid-β might be triggering this cell death, and propose a novel class of therapeutic approaches that will interfere in this link. Given the artificial nature of animal models in Alzheimer's research, and the comparatively sparse nature of human data, it is good to adopt a cautious wait and see a...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
(Florida Atlantic University) Few studies have examined how the neighborhood's physical environment relates to cognition in older adults. Researchers categorized 4,716 individuals by apolipoprotein E (APOE) genotype -- a genetic risk factor for Alzheimer's disease (AD) to determine if there are cognitive benefits of living in neighborhoods with greater access to social, walking and retail destinations. Results showed that the positive influence of neighborhood environments on cognition are strongest among those who are at the lowest risk for AD, specifically APOEε2 carriers.
Source: EurekAlert! - Social and Behavioral Science - Category: International Medicine & Public Health Source Type: news
(American Chemical Society) It seems too good to be true: a single drug that could treat humanity's worst afflictions, including atherosclerosis, cancer, Alzheimer's, Parkinson's and arthritis. All of these diseases have one thing in common -- they involve an inflammatory protein called NLRP3. Now, biotech start-ups and pharmaceutical companies are racing to develop drugs that inhibit the function of this protein, according to an article inChemical&Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society.  
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Alzheimer's | Biotechnology | Neurologists